— BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders — qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study — Proof of Mechanism and target engagement in the brain was established using blood…


Previous articleAlgernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
Next articlePT430 – Psychedelics for Eating Disorders, Davos’ House of Psychedelics, and The Future of the Synthesis Institute